Travere Therapeutics
NEWS
Retrophin, based in San Diego, announced that the U.S. Food and Drug Administration (FDA) had given its 100 mg and 300 mg tablets of Thiola EC (tiopronin) the thumbs-up to treat cystinuria.
July looks to be a quiet month for the U.S. Food and Drug Administration (FDA), and it sure looks like the agency is trying to get a lot of work done before the July 4 holiday. Here’s a look at the many approvals scheduled for this week.
Two weeks after filing a lawsuit against his former company from prison, Martin Shkreli has reached a settlement with Retrophin.
Retrophin, Inc. announced that it has entered into a three-way Cooperative Research and Development Agreement with the National Institutes of Health’s National Center for Advancing Translational Sciences and patient advocacy foundation Alagille Syndrome Alliance to collaborate on research efforts aimed at the identification and development of potentially novel therapeutics for Alagille syndrome.
Retrophin, Inc. announced that Company management will present at the following upcoming investor conferences in June
Ms. Poole brings more than 25 years of biopharmaceutical product development and manufacturing experience to Retrophin
Retrophin, Inc. reported its first quarter 2019 financial results and provided a corporate update.
Retrophin, Inc. announced it will report first quarter 2019 financial results on Tuesday, May 7, 2019 after the close of the U.S. financial markets.
Retrophin, Inc. announced that Eric Dube, Ph.D., chief executive officer, will present at the following upcoming investor conferences in March
JOBS
IN THE PRESS